-
Abstract Number: 1364
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
-
Abstract Number: 1365
Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
-
Abstract Number: 1366
Self-joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?
-
Abstract Number: 1367
An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis
-
Abstract Number: 1368
One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk
-
Abstract Number: 1369
Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy
-
Abstract Number: 1370
Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
-
Abstract Number: 1371
Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)
-
Abstract Number: 1372
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
-
Abstract Number: 1373
Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice
-
Abstract Number: 1374
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
-
Abstract Number: 1375
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
-
Abstract Number: 1376
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
-
Abstract Number: 1377
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome
-
Abstract Number: 1378
High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
- « Previous Page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- …
- 198
- Next Page »